PF-Atlas › Clinical Trials › NCT00563212

A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis

aerosol interferon-gamma · Phase 1

Registry ID
NCT00563212
Phase
Phase 1
Status
Completed
Drug / intervention
aerosol interferon-gamma
Sponsor
NYU Langone Health
Start
2007-01
Enrollment
12
Locations
1

About this trial

Idiopathic pulmonary fibrosis (IPF) is a progressive disease for which there is no effective treatment. Interferon-gamma is a medication that has been used for other lung diseases to decrease scarring and fibrosis. Studies of interferon-gamma injected under the skin did not show any improvement in survival in patients with IPF. We hypothesize that giving interferon-gamma as a nebulized mist directly into the lungs can affect the immune system in a way that decreases fibrosis.

View NCT00563212 on ClinicalTrials.gov →

Explore related

All aerosol interferon-gamma trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT00563212 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.